Clone JAMA147 is widely used in vivo in mice to block IL1 receptor type 1 (IL1R1; CD121a) signaling, thereby functionally inhibiting interleukin1 (IL1)–dependent immune responses. Its primary application is the experimental modulation of immune and inflammatory pathways mediated by IL1.

Key in vivo applications include:

• IL1R blockade: JAMA147 is used to prevent the binding of IL1 (both IL1α and IL1β) to its receptor, thereby suppressing all downstream biological effects of IL1, such as inflammation, fever, and leukocyte recruitment.
• Modeling and dissecting inflammatory diseases: By blocking IL1R1, JAMA147 facilitates the study of the role of IL1 signaling in disease models of autoimmunity, infection, skin inflammation, and other immunemediated pathologies.
• Studying celltypespecific contributions: Since IL1R1 is expressed on a range of cell types (T cells, dendritic cells, fibroblasts, epithelial cells, vascular endothelial cells, neural cells), JAMA147 enables researchers to probe the function of IL1 responses in diverse tissues in vivo.
• Testing therapeutic approaches: The antibody can be used to assess the therapeutic potential of IL1 pathway blockade in preclinical models, supporting the development of antiinflammatory drugs.

Additional context:

• JAMA147 is a hamster monoclonal antibody, often administered systemically (e.g., by intraperitoneal or intravenous injection) in murine models.
• According to supplier datasheets and published literature, recommended use cases are both in vivo and in vitro blockade of IL1R1.
• The blockade is specific to mouse IL1R1 and has been validated for inhibition of IL1–mediated effects such as cytokine production, leukocyte migration, and tissue swelling.

In summary, JAMA147 is the standard tool for in vivo neutralization of IL1 signaling in mouse models, providing a method to modulate and study inflammatory and immune responses mediated by this crucial cytokine pathway.

Other commonly used antibodies and proteins with JAMA147 in the literature primarily include other monoclonal antibodies against mouse IL1 receptor (CD121a) and antibodies targeting interleukin1 (IL1) itself.

Key examples include:

• JAMA83: Recognizes a distinct epitope on type I IL1 receptor and is frequently used alongside JAMA147 for comparative or combinatorial studies.
• JAMA84: Recognizes another distinct epitope on the same receptor, often coused for epitope mapping, functional inhibition, and binding competition studies.
• JAMA110: Targets a separate epitope from JAMA147, used for multifaceted analyses of receptor function and blocking activity.
• M15 and 35F5: Earlier generation rat monoclonal antibodies specific for murine type I IL1 receptor, used to benchmark JAMA147’s inhibitory potency and specificity.

Additionally, antibodies against IL1α and IL1β are sometimes pooled with antiIL1R antibodies, including JAMA147, to achieve broad blockade of IL1 signaling in functional studies.

These combinations are routinely applied in:

• Competition and epitope mapping assays
• Neutralization or inhibition studies
• In vivo functional blockades of IL1 activity

JAMA147 is most effective when its unique binding specificity is combined with antibodies targeting alternate IL1R epitopes or the ligand itself, providing a comprehensive blockade of the IL1 signaling axis.

The key findings from the citations of clone JAMA147 in scientific literature primarily relate to its application as a monoclonal antibody targeting mouse interleukin1 receptor type 1 (IL1R1), also known as CD121a. This antibody is used for various immunological studies, particularly in the context of inflammation and antiviral T cell responses. Here are some of the main uses and findings:

1. IL1 Binding Prevention: Clone JAMA147 prevents IL1 from binding to the type I IL1 receptor, which is crucial for mediating biological responses to IL1α and IL1β. This blocking capability is essential for studying the role of IL1 in immune responses and inflammation.

2. In Vivo and In Vitro Applications: The antibody is used both in vivo and in vitro for IL1R1 blockade. It is recommended for functional assays and receptor blocking experiments, highlighting its versatility in different research settings.

3. Expression on Multiple Cell Types: The IL1 receptor type I is expressed on various cell types, including T cells, thymocytes, dendritic cells, fibroblasts, vascular endothelial cells, epithelial cells, and neural cells. This broad expression profile makes the JAMA147 antibody a valuable tool for studying IL1R1 in different cellular contexts.

4. Immune Response Studies: The antibody has been cited in studies examining immune responses, such as those involving neutrophils and other immune cells, contributing to a deeper understanding of IL1's role in immune modulation.

These findings collectively underscore the significance of clone JAMA147 in unraveling the complex roles of IL1R1 in immunology and inflammation.

Clone JAMA147 is a monoclonal antibody against mouse IL1 receptor (CD121a), used primarily for IL1 blockade in research settings. The dosing regimens for this clone can vary depending on the specific experimental model or research question. Here’s a general overview of how it might be used across different mouse models:

1. Dose and Administration:

   • Intraperitoneal (i.p.) Administration: The typical dose for clone JAMA147 is a single administration of 4 mg/kg, given intraperitoneally. This method is commonly used in mouse studies to block IL1 receptor activity.

2. Frequency of Administration:

   • The frequency can vary based on the study design. For some studies, a single dose might be sufficient, while others may require repeated doses, such as every other day, depending on the experimental design and the duration of the study.

3. Experimental Models:

   • Cancer Models: In cancer research, IL1 blockade with clone JAMA147 might be part of a combination therapy to evaluate its effects on tumor growth or treatment outcomes.
   • Inflammatory Models: This antibody is used to study the role of IL1 in inflammation. Different models of inflammation may require different dosing schedules depending on the progression of the disease and the specific inflammatory pathways being studied.

4. Mouse Strains and Age:

   • The dosing regimen might need adjustments based on the mouse strain or age, as these factors can influence the immune response and drug pharmacokinetics. However, specific data on these variations is not detailed in the available literature.

In summary, while the standard dosing regimen for clone JAMA147 in mouse models is typically a 4 mg/kg i.p. dose, adjustments may be necessary depending on the specific research question, experimental model, and desired duration of IL1 blockade.